Evidence map›Paper›PMID 32366559›Full record

ArticleAnnals of clinical and laboratory science2020

Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.

Janice S Ahn, Ali Al-Habib, Jeffrey A Vos, Aliyah R Sohani, Oralia Barboza-Quintana, Juan P Flores, Sijin Wen, Flavia G Rosado

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Annals of clinical and laboratory science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Janice S AhnDepartment of Pathology, Anatomy and Laboratory Medicine, West Virginia University, Morgantown, WV, USA.
Ali Al-HabibDepartment of Pathology and Laboratory Medicine, University of Texas Health Sciences Center at Houston, Houston, TX, USA.
Jeffrey A VosDepartment of Pathology, Anatomy and Laboratory Medicine, West Virginia University, Morgantown, WV, USA.
Aliyah R SohaniDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Oralia Barboza-QuintanaDepartment of Pathology, University Hospital Dr. Jose Eleuterio Gonzalez, Monterrey, Mexico.
Juan P FloresDepartment of Pathology, University Hospital Dr. Jose Eleuterio Gonzalez, Monterrey, Mexico.
Sijin WenDepartment of Biostatistics, West Virginia University, Morgantown, WV, USA.
Flavia G RosadoDepartment of Pathology, UT Southwestern Medical Center, Dallas, TX, USA Flavia.rosado@utsouthwestern.edu.
West Virginia University · USMassachusetts General Hospital · USThe University of Texas Health Science Center at Houston · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

This study aims to characterize the tumor microenvironment of plasmablastic lymphoma (PBL) in regard to the quantities of CD163(+) tumor associated macrophages (TAM) and PD1(+) tumor infiltrating lymphocytes (TIL). This article also reviews the existing knowledge of the role of PD-1/PD-L1 pathway in the tumor microenvironment of hematopoietic neoplasms, discusses potential mechanisms to explain our findings, and outlines areas for future studies. We performed CD163 and PD1 immunohistochemical studies in 11 cases classified as plasmablastic lymphoma, and recorded the percentages of positive TAMs and TILs. Based on previous studies, cut off values of ≥30% and >5% were used to classify the cases into high TAMs and TILs, respectively. We determined that the majority of cases (8 of 11, or 73%) had high percentage of TAMs, while only a minority had high percentage of TILs (3 of 11, or 27%). Our data shows a trend towards a negative correlation between TAMs and TILs (

Indexed as

AdultAgedAntigens, CDAntigens, Differentiation, MyelomonocyticB7-H1 AntigenBiomarkers, TumorCD163 AntigenFemaleHumansImmunohistochemistryLymphocytes, Tumor-InfiltratingMacrophagesMaleMiddle AgedPlasmablastic LymphomaPrognosisAntigens, CDAntigens, Differentiation, MyelomonocyticB7-H1 AntigenBiomarkers, TumorCD163 AntigenCD274 protein, humanReceptors, Cell SurfaceCD163PD-1plasmablastic lymphomatumor microenvironment

Identifiers

PMID32366559
PMCPMC7439522
OpenAlexW3023406791

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.